As James S. has pointed out, they seemed to be tight-lipped at the moment. Presentation not updated and upcoming investor/analyst day on the 28th. Clinical trial status will be updated according to the PR. Maybe we'll hear news about the lung cancer trial start and the aim2cerv trial. Having been disappointed in the past with the outcome of conferences, not with the updates which have been very good but with the market's reaction, I remain modestly optimistic.
Too bad it couldn't have been you, instead. Her life was worth saving.
Blue, I wouldn't normally respond to his comment like that but to use the patient's death as a tool to short and bash (when the FDA agreed it had nothing to do with the vaccine) triggered something in me.
I don't know, phuqphace but I believe you are in error.
Make sure he uses toilet paper and not his tongue! You don't know where that tongue has been!
Anyone tried calling Hans Vitzthum, the IR person Greg had helping out for clarification? He's with LifeSci Advisors, LLC. He's been pretty responsive in the past.
I found the # for LifeSci, 646.597.6979. I'd try to call but am on the road with spotty reception.